WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Tuesday, May 16, 2017

ATCC and Michael J. Fox Foundation Teamed Up to Discuss Parkinson’s Research Tools

BY MAGDALENA KEGEL



Experts from ATCC — a leading nonprofit repository of biological materials — partnered with the Michael J. Fox Foundation for Parkinson’s Research for a workshop at the recent International Society for Biological and Environmental Repositories (ISBER) 2017 Annual Meeting.
The workshop aimed to address best practices for providing researchers with biological materials of high quality. But the spotlight was particularly focused on the Michael J. Fox Foundation’s (MJFF) Pre-clinical Tools Program, a collection of research tools made available to promote research into Parkinson’s disease mechanisms and treatments.
The workshop, named “MJFF and ATCC Partnering for Success,” was held on the second day of the meeting, which took place May 9-12 in Toronto, Canada.
Liz Kerrigan, director of Commercial Partnerships and Standards, and Maryellen de Mars, PhD, senior director of Standards Resource Center, who represented ATCC, teamed up with the Nicole Polinski, PhD, MJFF’s associate director of research programs, for the workshop.
“Research tools and reference reagents enable scientists to gain insight into the mechanisms of disease, and are critical in the development of new treatments,” Dr. Raymond Cypess, ATCC’s chairman and CEO, said in a press release.
“These tools and reagents are also critical in recruiting scientists to work in specific disease areas. As partners to the scientific community for more than 90 years, ATCC is proud to join MJFF at ISBER to discuss the significance of these tools and the need to increase access and availability for the global research community.”
The workshop wasn’t the first time ATCC took an interest in Parkinson’s disease. In 2016, the company released three lab-grown cell types allowing researchers to explore the biological role of LRRK2 — identified as a risk gene in the disease.
The development of the cell lines was funded by the foundation, which continues to work with ATCC to develop cells that produce the Parkinson’s-linked protein parkin. Such cell lines are predicted to be available in late 2017.
“The Michael J. Fox Foundation’s collaboration with ATCC delivers vital pre-clinical tools to the Parkinson’s research community to address field-wide challenges and advance disease understanding,” Polinski said. “We are pleased to join ATCC at ISBER to highlight the importance of these tools in developing therapeutic strategies and speeding [Parkinson’s disease] research.”
https://parkinsonsnewstoday.com/2017/05/16/atcc-and-michael-j-fox-foundation-mjff-teamed-up-discuss-parkinsons-research-tools/ 

No comments:

Post a Comment